Chemosensitizing anti-cancer activity of LFM-A13, a leflunomide metabolite analog targeting polo-like kinases

Cell Cycle

Volumn 6, Issue 24, 2007, Pages 3021-3026

  Uckun, Fatih M ^a  

^a Parker Hughes Cancer Center   (United States)

Author keywords

Cancer; Cell cycle; Chemotherapy; Spindle; Transgenic mice

Indexed keywords

CYCLIN DEPENDENT KINASE ACTIVATING KINASE; DEATH ASSOCIATED PROTEIN KINASE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; LEFLUNOMIDE; MIDOSTAURIN; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE KINASE 4; POLO LIKE KINASE; PROTEIN SERINE THREONINE KINASE; RAF PROTEIN; STRESS ACTIVATED PROTEIN KINASE;

ANIMAL EXPERIMENT; ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CANCER CELL CULTURE; CELL CYCLE PROGRESSION; CHEMOSENSITIZATION; CONTROLLED STUDY; CYTOTOXICITY; DOG; DRUG INHIBITION; FLOW CYTOMETRY; IC 50; MITOSIS SPINDLE; MOUSE; NONHUMAN; REVIEW; TUMOR GROWTH;

CANIS FAMILIARIS; MUS MUSCULUS; RODENTIA;

EID: 38149122052     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.6.24.5096     Document Type: Review

References (24)

1. Martin BT, Strebhardt K. Polo-like kinase 1: Target and regulator of transcriptional control. Cell Cycle 2006; 5:2881-5.
2. Van de Weerdt BCM, Medema RH. Polo-like kinases: A team in control of the division. Cell Cycle 2006; 5:853-64.
3. Strebhardt K, Kneisel L, Linhart C, Bernd A, Kaufmann R. Prognostic value of pololike kinase expression in melanomas. JAMA 2000; 283:479-80.
4. Takai N, Miyazaki T, Fujisawa K, Nasu K, Hamanaka R, Miyakawa I. Expression of polo-like kinase in ovarian cancer is associated with histological grade and clinical stage. Cancer Letters 2001; 164:41-9.
5. Tokumitsu Y, Mori M, Tanaka S, Akazawa K, Nakano S, Niho Y. Prognostic significance of polo-like kinase expression in esophageal carcinoma. Int J Oncol 1999; 15:687-92.
6. Wolf G, Elez R, Doermer A, Holtrich U, Ackermann H, Stutte HJ, Altmannsberger HM, Rübsamen-Waigmann H, Strebhardt K. Prognostic significance of polo-like kinase (PLK) expression in non- small cell lung cancer. Oncogene 1997; 14:543-9.
7. Kanaji S, Saito H, Tsujitani S, Matsumoto S, Tatebe S, Kondo A, Ozaki M, Ito H, Ikeguchi M. Expression of polo-like kinase 1 (PLK1) protein predicts the survival of patients with gastric carcinoma. Oncology 2006; 70:126-33.
8. Reagan-Shaw S, Ahmad N. Polo-like kinase (Plk) as a target for prostate cancer management. IUBMB Life 2005; 57(10):677-82.
9. Weichert W, Kristiansen G, Winzer KJ, Schmidt M, Gekeler V, Noske A, Müller BM, Niesporek S, Dietel M, Denkert C. Polo-like kinase isoforms in breast cancer: Expression patterns and prognostic implications. Virchows Arch 2005; 446:442-50.
10. Spankuch B, Heim S, Kurunci-Csacsko E, Lindenau C, Yuan J, Kaufmann M, Strebhardt K. Down-regulation of polo-like kinase 1 elevates drug sensitivity of breast cancer cells in vitro and in vivo. Cancer Res 2006; 66:5836-46.
11. Liu X, Erickson RL. Polo-like kinase (Plk) depletion induces apoptosis in cancer cells. Proc Natl Acad Sci USA 2003; 100:5789-94.
12. Spänkuch-Schmitt B, Bereiter-Hahn J, Kaufmann M, Strebhardt K. Effect of RNA silencing of polo-like kinase-1 (Plk-1) on apoptosis and spindle formation in human cancer cells. JNCI 2002; 94:1863-77.
13. Spankuch B, Matthes Y, Knecht R. Cancer inhibition in nude mice after systemic application of U6 promoter-driven short hairpin RNAs against PLK1. JNCI 2004; 96:862-72.
14. Spänkuch-Schmitt B, Wolf G, Solbach C, Loibl S, Knecht R, Stegmüller M, von Minckwitz G, Kaufmann M, Strebhardt K. Downregulation of human polo-like kinase activity by antisense oligonucleotides induces growth inhibition in cancer cells. Oncogene 2002; 21:3162-71.
15. Uckun FM, Dibirdik I, Qazi S, Vassilev A, Ma H, Mao C, Benyumov A, Emami KH. Anti-breast cancer activity of LFM-A13, a potent inhibitor of Polo-like kinase (PLK). Bioorg Med Chem 2007; 15:800-14.
16. Mahajan S, Ghosh S, Sudbeck EA, Zheng Y, Downs S, Hupke M, Uckun FM. Rational design and synthesis of a novel antileukemic agent targeting Bruton's tyrosine kinase (BTK), LFM-A13 [alpha-cyano-betahydroxy-beta- methyl-N-(2, 5-dibromophenyl)propenamidel." J Biol Chem 1999; 274:9587-99.
17. Tibbles HE, Samuel P, Erbeck D, Mahajan S, Uckun FM. In vivo toxicity and anti-thrombotic profile of the oral formulation of the antileukemic agent, LFM-A13-F. Arzneimittelforschung 2004; 54:330-9.
18. Uckun FM, Vassilev AO, Dibirdik I, Liu XP, Erbeck D, Tibbles HE, Qazi S, Venkatachalam TK. Anti-cancer activity profile of 3′-azidothymidine 5′-[p-methoxyphenyl methoxyalaninyl phosphate] (Compound 003), a novel nucleoside analog. Arzneimittelforschung 2004; 54:715-31.
19. Navara CS, Benyumov A, Vassilev A, Narla RK, Ghosh P, Uckun FM. Vanadocenes as potent anti-proliferative agents disrupting mitotic spindle formation in cancer cells. Anticancer Drugs 2001; 12(4):369-76.
20. Uckun FM, Zheng Y, Cetkovic-Cvrlje M, Vassilev A, Lisowski E, Waurzyniak B, Chen H, Carpenter R, Chen CL. In vivo pharmacokinetic features, toxicity profile, and chemosensitizing activity of alpha-cyano-beta-hydroxy-beta- methyl-N-(2,5-dibromophenyl)propenamide (LFM-A13), a novel antileukemic agent targeting Bruton's tyrosine kinase. Clin Cancer Res 2002; 8:1224-33.
21. McInnes C, Mezna M, Fischer PM. Progress in the discovery of polo-like kinase inhibitors. Curr Top Med Chem 2005; 5:181-97.
22. Strebhardt K, Ullrich A. Targeting polo-like kinase 1 for cancer therapy. Nat Rev Cancer 2006; 6:321-30.
23. DuMez D, Venkatachalam TK, Uckun FM. Large-scale synthesis of GMP grade a-cyano-b-hydroxy-b-methyl-N-(2,5-dibromophenyl) propenamide (LFM-A13), a new anti-cander drug candidate. Arzneimittelforschung 2007; 57:155-63.
24. Uckun FM, Tibbles H, Venkatachalam TK, DuMez D, Erbeck D. Preclinical toxicity and pharmacokinetics of the BTK-targeting antileukemic drug candidate, a-cyano-b-hydroxy-b-methyl-N-(2,5-dibromophenyl) propenamide (LFM-A13). Arzneimittelforschung 2007; 57:31-46.